Investors watching the COVID-19 vaccine development process could be forgiven for thinking it's not so hard. The effort has moved extraordinarily quickly so far, and with few hiccups. That isn’t how things usually go, especially for new diseases. The world got a reminder Tuesday as ...
For Max Nisen's latest contributions to The Japan Times, see below:
The FDA usually wants high standards while drugmakers push boundaries. But political pressure and public unease over a rushed process has forced a role reversal.
Pandemics make for strange bedfellows.
Everything would have to go right to get a vaccine this year, but several types of treatments may be able to help patients in a matter of months.
Positive study results have arrived quickly, but the next steps will be slower.
Most candidates won’t work, but it’s essential to be ready to mass-produce the one that does.